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Prognostic value of
circulating chromogranin A
levels in acute coronary
syndrome
We refer to the orginal paper by Jansson
et al.
1 to which we would like to address
some comments.
Chromogranin A (CgA) has been accepted
as a marker for the neuroendocrine tumours
(NET), with some limits concerning its value
for diagnostic purposes, and greater strength
for monitoring their treatment.
Chromogranin A levels in patients with
NET, however, often are markedly increased.
In the group of patients with acute coronary
syndromes (ACS) studied by Jansson et al.,
CgA levels were only slightly or moderately
increased, reaching the levels observed in
numerous other pathological conditions of
which some most important and frequently
occurring are: occult gastric inﬂammation
caused by Helicobacter pylori, atrophic gastri-
tis, some chronic bowel inﬂammatory dis-
eases, renal or hepatic insufﬁciency, benign
prostatic hypertrophy, hypertension with
increased sympathetic tone, rheumatoid
arthritis.
2,3
Raised CgA levels can be induced by
various drugs: not only proton-pump inhibi-
tors but also H-2 antagonists, glucocorticoids
and various other drugs acting on sympathetic
tone activity or stimulating release of endo-
genic catecholamines. Finally, an increase of
CgA level may appear after consumption of
a meal.
4
Apart from that, another important issue is
the method of blood collection, as CgA level
appears to be 30–50% higher when measured
in EDTA plasma than in serum.
5,6
All these matters mean that it seems hard
to accept the author’s conclusion that CgA
plasma levels obtained within the ﬁrst 24 h
of admission can be independently associated
with the incidence of death in patients with
ACS, and therefore may have prognostic
value.
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Prognostic value of
circulating chromogranin
A levels in acute coronary
syndrome: reply
In their letter to the editor, Jeske et al. make
some comments relevant to our article
entitled: ‘Prognostic value of circulating
chromogranin A level in acute coronary syn-
dromes’ recently published in the European
Heart Journal.
1 First, the observation that
chromogranin A (CgA) levels in our patients
were only moderately elevated compared
with levels in the normal population is
consistent with prior ﬁndings in other
cohorts of patients with acute coronary syn-
dromes (ACS).
2,3 Despite of this, even only
mildly to moderately elevated CgA levels dis-
criminate well between patients with a
favourable and poor prognosis in various
types of heart disease,
2–4 suggesting that
CgA elevation reﬂects detrimental processes
speciﬁc to the subgroup of patients with
acute myocardial ischaemia and a poor prog-
nosis, and not processes found in ACS
patients in general. Of note, fourth quartile
CgA levels (.33.7 U/L) in our patients were
clearly increased compared with reference
values (,18 U/L), demonstrating that a pro-
portion of ACS patients has clearly elevated
CgA levels. As these patients also had the
highest number of events during follow-up,
CgA seems to identify the subgroup of ACS
patients with an unfavourable prognosis.
Jeske et al. also raise an important question
regarding the impact of comorbidities on CgA
levels in patients with heart disease. We
clearly show that CgA levels in our patients
are inﬂuenced by a number of factors, includ-
ing reduced renal function. However, by
multivariate Cox proportional hazard
regression analysis used in our study, we
adjusted for these confounders and found
that CgA levels provided independent prog-
nostic information to conventional risk
markers. We acknowledge that we lack infor-
mation on some of the conditions mentioned
by Jeske et al., including gastric inﬂammation
by H. pylori, atrophic gastritis, and benign
hypertrophy of the prostate, but we believe
it is unlikely that these conditions had a
major impact on mortality or the secondary
endpoints in our study. In fact, we believe
that the presence of these factors would
have tended to obscure the association
between CgA levels and events in our study.
Similarly, the inﬂuence on CgA levels by medi-
cations generally not considered harmful to
patients with heart disease would also be
expected to attenuate the association
between CgA levels and outcome in our
patients. Thus, the major novel ﬁnding of
our study is that CgA levels, although being
inﬂuenced by comorbidities and medications,
still provided independent prognostic
information in patients with ACS. More
importantly, CgA also provided incremental
information to the information obtained by
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European Heart Journal (2010) 31, 128–129estimating left ventricular ejection fraction,
and measuring the contemporary cardiac
biomarkers, troponin T, and pro-BNP.
Finally, as is the case for all biochemical
markers, analytical issues must be taken into
account when evaluating CgA measurements.
5
However, as all our measurements were per-
formed in serum and with the same method,
this should not be a problem in our study.
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